Therapeutic targeting of BET bromodomain and other epigenetic acetylrecognition domain-containing factors

Area of Science:

• Epigenetics
• Molecular Oncology
• Drug Discovery

Background:

• Cancer therapies are increasingly targeting chromatin modifiers and transcriptional regulators.
• Understanding epigenetic mechanisms is crucial for developing novel oncogenesis treatments.
• Histone lysine acetylation recognition by chromatin-associated factors is a key focus.

Purpose of the Study:

• To review cancer therapies targeting chromatin-associated factors that recognize histone lysine acetylation.
• To discuss the safety and efficacy of bromodomain and extraterminal domain (BET) family protein inhibitors.
• To explore potential strategies for targeting BRD4-PTEFb, SWI/SNF, TAF1, and GAS41.

Main Methods:

• Literature review of recent safety and efficacy data for BET inhibitors.
• Analysis of clinical trial performance in the context of BRD4-PTEFb targeting.
• Discussion of emerging therapies targeting SWI/SNF, TAF1, and GAS41.

Main Results:

• BET inhibitors show reported safety and efficacy, with ongoing evaluation of BRD4-PTEFb targeting strategies.
• New therapies targeting bromodomain-containing factors in SWI/SNF complexes are under development.
• Potential for targeting TAF1 and GAS41, highlighting selectivity in acetyl-recognition.

Conclusions:

• Further development of epigenetic therapies is promising, particularly proximity-based approaches.
• Targeting histone acetylation recognition offers a significant avenue for cancer treatment innovation.
• Understanding selectivity and combinatorial specificity is key for future drug design.